suramin has been researched along with Cancer of Colon in 28 studies
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this report we demonstrated that [3H]suramin enters polarized human colon adenocarcinoma cells when added to the apical side of the monolayer." | 7.68 | Autoradiographic localization of tritiated suramin in polarized human colon adenocarcinoma cells. ( Baghdiguian, S; Boudier, JA; Boudier, JL; Fantini, J, 1993) |
| "Suramin, a drug that binds to several types of growth factors, has been previously shown to induce the enterocyte-like differentiation of HT29-D4 human colonic adenocarcinoma cells, suggesting that growth factors are involved in such a process." | 7.68 | Potential autocrine role of insulin-like growth factor II during suramin-induced differentiation of HT29-D4 human colonic adenocarcinoma cell line. ( el Atiq, F; Garrouste, FL; Marvaldi, JL; Pommier, GJ; Remacle-Bonnet, MM; Roccabianca, M, 1992) |
| "Suramin, a drug currently used for advanced malignancy, induces the differentiation of the human colonic adenocarcinoma cell clone HT29-D4 and this process is correlated with a decreased glycolytic activity." | 7.68 | The concentration of glucose in the culture medium determines the effect of suramin on the growth and differentiation of the human colonic adenocarcinoma cell clone HT29-D4. ( Baghdiguian, S; Brunet, M; Fantini, J; Marvaldi, J; Rabenandrasana, C; Roccabianca, M, 1990) |
| "At present there is no effective treatment for cachexia." | 5.29 | Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo. ( D'Alessandro, F; Fong, M; Freter, CE; Nordan, RP; Strassmann, G; Windsor, S, 1993) |
| "Suramin is a polysulphonated naphthylurea currently investigated for the treatment of advanced malignancy." | 5.29 | Intracellular localisation of suramin, an anticancer drug, in human colon adenocarcinoma cells: a study by quantitative autoradiography. ( Baghdiguian, S; Boudier, JA; Boudier, JL; Fantini, J, 1996) |
| "In this report we demonstrated that [3H]suramin enters polarized human colon adenocarcinoma cells when added to the apical side of the monolayer." | 3.68 | Autoradiographic localization of tritiated suramin in polarized human colon adenocarcinoma cells. ( Baghdiguian, S; Boudier, JA; Boudier, JL; Fantini, J, 1993) |
| "Suramin, a drug that binds to several types of growth factors, has been previously shown to induce the enterocyte-like differentiation of HT29-D4 human colonic adenocarcinoma cells, suggesting that growth factors are involved in such a process." | 3.68 | Potential autocrine role of insulin-like growth factor II during suramin-induced differentiation of HT29-D4 human colonic adenocarcinoma cell line. ( el Atiq, F; Garrouste, FL; Marvaldi, JL; Pommier, GJ; Remacle-Bonnet, MM; Roccabianca, M, 1992) |
| "Suramin, a drug currently used for advanced malignancy, induces the differentiation of the human colonic adenocarcinoma cell clone HT29-D4 and this process is correlated with a decreased glycolytic activity." | 3.68 | The concentration of glucose in the culture medium determines the effect of suramin on the growth and differentiation of the human colonic adenocarcinoma cell clone HT29-D4. ( Baghdiguian, S; Brunet, M; Fantini, J; Marvaldi, J; Rabenandrasana, C; Roccabianca, M, 1990) |
| "(c) Suramin-treated rats had markedly decreased lymphocyte stimulation, pointing to a possible immunosuppressive effect." | 1.30 | Effects of suramin on anastomotic colon tumors in a rat model. ( De Clerck, LS; Dirix, L; Eyskens, E; Hendriks, J; Hubens, A; Hubens, G; Lauwers, P; Schuerwegh, A; Stevens, WJ; Van Marck, E; Vermeulen, P, 1999) |
| "At present there is no effective treatment for cachexia." | 1.29 | Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo. ( D'Alessandro, F; Fong, M; Freter, CE; Nordan, RP; Strassmann, G; Windsor, S, 1993) |
| "Suramin is a polysulfonated compound currently under investigation for the treatment of various types of cancer." | 1.29 | Co-localization of suramin and serum albumin in lysosomes of suramin-treated human colon cancer cells. ( Baghdiguian, S; Boudier, JA; Boudier, JL; Fantini, J, 1996) |
| "Suramin is a polysulphonated naphthylurea currently investigated for the treatment of advanced malignancy." | 1.29 | Intracellular localisation of suramin, an anticancer drug, in human colon adenocarcinoma cells: a study by quantitative autoradiography. ( Baghdiguian, S; Boudier, JA; Boudier, JL; Fantini, J, 1996) |
| "Suramin is an anti-cancer drug which induces the differentiation of the human colon cancer clone HT29-D4." | 1.28 | Short-term suramin treatment followed by the removal of the drug induces terminal differentiation of HT29-D4 cells. ( Baghdiguian, S; Fantini, J; Marvaldi, J; Verrier, B, 1992) |
| "Suramin is an anti-helminthic drug that has been shown to antagonize the effects of a variety of growth factors including EGF, PDGF and TGF beta." | 1.28 | [Suramin inhibits the proliferation and stimulates the differentiation of tumoral cell lines HT29-D4 and C6]. ( Baghdiguian, S; Fantini, J; Marvaldi, J; Pichon, J, 1991) |
| "Suramin is a polyanionic compound currently used under evaluation for antineoplastic activity." | 1.28 | Double screening of suramin derivatives on human colon cancer cells and on neural cells provides new therapeutic agents with reduced toxicity. ( Baghdiguian, S; Fantini, J; Nickel, P, 1991) |
| "Suramin is a polysulfonated naphthylurea currently investigated for the treatment of advanced malignancy." | 1.28 | A suramin derivative induces enterocyte-like differentiation of human colon cancer cells without lysosomal storage disorder. ( Baghdiguian, S; Fantini, J; Marvaldi, J; Nickel, P, 1990) |
| "The human colon cancer cell line HT-29 produces a growth factor (CRDGF; Mr = 25,000) which inhibits EGF binding to a wide variety of different normal and tumoral cell types in culture." | 1.27 | Autocrine secretion of a colorectum-derived growth factor by HT-29 human colon carcinoma cell line. ( Bettetini, D; Culouscou, JM; Garrouste, F; Marvaldi, J; Pommier, G; Remacle-Bonnet, M, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (10.71) | 18.7374 |
| 1990's | 24 (85.71) | 18.2507 |
| 2000's | 1 (3.57) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nylund, G | 1 |
| Nordgren, S | 1 |
| Delbro, DS | 1 |
| Pommier, G | 4 |
| Garrouste, F | 2 |
| el Atiq, F | 2 |
| Marvaldi, J | 10 |
| Remacle-Bonnet, M | 2 |
| Strassmann, G | 1 |
| Fong, M | 1 |
| Freter, CE | 1 |
| Windsor, S | 1 |
| D'Alessandro, F | 1 |
| Nordan, RP | 1 |
| Baghdiguian, S | 12 |
| Boudier, JA | 4 |
| Boudier, JL | 3 |
| Fantini, J | 15 |
| Anees, M | 1 |
| Reynolds, S | 1 |
| Rajagopal, S | 1 |
| Chakrabarty, S | 1 |
| Lauwers, P | 1 |
| Hubens, G | 1 |
| Hendriks, J | 1 |
| Vermeulen, P | 1 |
| Schuerwegh, A | 1 |
| Stevens, WJ | 1 |
| De Clerck, LS | 1 |
| Dirix, L | 1 |
| Van Marck, E | 1 |
| Hubens, A | 1 |
| Eyskens, E | 1 |
| Rodier, JM | 1 |
| Pujade-Lauraine, E | 1 |
| Verrier, B | 5 |
| Gerard, C | 1 |
| Pommier, GJ | 1 |
| Garrouste, FL | 1 |
| Roccabianca, M | 3 |
| Marvaldi, JL | 1 |
| Remacle-Bonnet, MM | 1 |
| Leith, JT | 2 |
| Papa, G | 1 |
| Quaranto, L | 1 |
| Michelson, S | 2 |
| Zappitelli, JP | 1 |
| Pichon, J | 2 |
| Nickel, P | 2 |
| Courillon-Mallet, A | 1 |
| Robert, C | 1 |
| Pic, P | 1 |
| Mauchamp, J | 1 |
| Rognoni, JB | 2 |
| Theveniau, M | 1 |
| Rabenandrasana, C | 1 |
| Brunet, M | 1 |
| Forgue-Lafitte, ME | 1 |
| Coudray, AM | 1 |
| Bréant, B | 1 |
| Mester, J | 1 |
| Culouscou, JM | 1 |
| Bettetini, D | 1 |
28 other studies available for suramin and Cancer of Colon
| Article | Year |
|---|---|
Expression of P2Y2 purinoceptors in MCG 101 murine sarcoma cells, and HT-29 human colon carcinoma cells.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Animals; Antineoplastic Agents; Blotting, Western; Ce | 2004 |
Potential role of IGFBPS in the regulation of the differentiation state of human colonic carcinoma cells.
Topics: Blotting, Western; Carrier Proteins; Cell Differentiation; Colonic Neoplasms; Humans; Insulin-Like G | 1993 |
Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo.
Topics: Adenocarcinoma; Animals; Cachexia; Colonic Neoplasms; Humans; Interleukin-6; Liver; Male; Mice; Mice | 1993 |
Autoradiographic localization of tritiated suramin in polarized human colon adenocarcinoma cells.
Topics: Adenocarcinoma; Autoradiography; Biological Transport; Cell Nucleus; Colonic Neoplasms; Cytoplasm; H | 1993 |
Co-localization of suramin and serum albumin in lysosomes of suramin-treated human colon cancer cells.
Topics: Antineoplastic Agents; Colonic Neoplasms; Gold; Humans; Lysosomes; Microscopy, Electron; Serum Album | 1996 |
Intracellular localisation of suramin, an anticancer drug, in human colon adenocarcinoma cells: a study by quantitative autoradiography.
Topics: Adenocarcinoma; Antineoplastic Agents; Autoradiography; Colonic Neoplasms; Humans; Microscopy, Elect | 1996 |
Location of tumour cells in colon tissue by Texas red labelled pentosan polysulphate, an inhibitor of a cell surface protease.
Topics: Carboxylic Ester Hydrolases; Cell Membrane; Chromatography, Affinity; Colonic Neoplasms; Dansyl Comp | 1996 |
Differentiation-inducing effect of retinoic acid, difluoromethylornithine, sodium butyrate and sodium suramin in human colon cancer cells.
Topics: Antineoplastic Agents; Butyrates; Carcinoembryonic Antigen; Cell Differentiation; Cell Division; Col | 1998 |
Effects of suramin on anastomotic colon tumors in a rat model.
Topics: Adenocarcinoma; Anastomosis, Surgical; Animals; Antineoplastic Agents; Cell Survival; Colon; Colonic | 1999 |
[Autocrine stimulation of cell proliferation in colonic carcinoma: a biological curiosity or a new therapeutic target?].
Topics: Antineoplastic Agents; Cell Division; Colonic Neoplasms; Epidermal Growth Factor; Humans; Neoplasm I | 1995 |
Insulin like growth factor I is an autocrine regulator of human colon cancer cell differentiation and growth.
Topics: Biological Transport; Cell Differentiation; Cell Division; Cell Polarity; Colonic Neoplasms; Fluores | 1992 |
Potential autocrine role of insulin-like growth factor II during suramin-induced differentiation of HT29-D4 human colonic adenocarcinoma cell line.
Topics: Adenocarcinoma; Carcinoembryonic Antigen; Carrier Proteins; Cell Differentiation; Cell Line; Colonic | 1992 |
Modification of the volumetric growth responses and steady-state hypoxic fractions of xenografted DLD-2 human colon carcinomas by administration of basic fibroblast growth factor or suramin.
Topics: Adenocarcinoma; Animals; Cell Division; Cell Line; Cell Survival; Colonic Neoplasms; Dose-Response R | 1992 |
[Suramin induces lysosomal storage disorder in HT29-D4 cells during a mechanism of polarized endocytosis].
Topics: Adenocarcinoma; Cell Line, Transformed; Cell Transformation, Neoplastic; Clone Cells; Colonic Neopla | 1992 |
Short-term suramin treatment followed by the removal of the drug induces terminal differentiation of HT29-D4 cells.
Topics: Cell Count; Cell Differentiation; Colonic Neoplasms; Electrophysiology; Glycolysis; HLA Antigens; Hu | 1992 |
[Suramin inhibits the proliferation and stimulates the differentiation of tumoral cell lines HT29-D4 and C6].
Topics: Adenocarcinoma; Animals; Cell Division; Cell Line, Transformed; Cell Transformation, Neoplastic; Col | 1991 |
Double screening of suramin derivatives on human colon cancer cells and on neural cells provides new therapeutic agents with reduced toxicity.
Topics: Antineoplastic Agents; Cell Division; Cell Line; Cell Survival; Colonic Neoplasms; Drug Screening As | 1991 |
Suramin and tumor cell radiosensitivity.
Topics: Colonic Neoplasms; Humans; Radiation-Sensitizing Agents; Suramin; Tumor Cells, Cultured | 1991 |
Kinetics of biochemical, electrophysiological and morphological events (including lysosomal disorder) during the course of suramin-induced differentiation of the human colon-cancer cell clone HT29-D4.
Topics: Cell Differentiation; Cell Line; Cell Membrane; Colonic Neoplasms; Electrophysiology; Epithelium; Hu | 1991 |
[The in vitro differentiation of cancer cells of the human colon (HT29-D4) is associated with the presence of annulate lamellae in the basal part of the cytoplasm].
Topics: Cell Transformation, Neoplastic; Colonic Neoplasms; Cytoplasm; Epithelium; Humans; In Vitro Techniqu | 1990 |
[Models for the study of cell differentiation].
Topics: beta-Galactosidase; Cell Differentiation; Colon; Colonic Neoplasms; Epithelial Cells; Epithelium; Hu | 1990 |
A suramin derivative induces enterocyte-like differentiation of human colon cancer cells without lysosomal storage disorder.
Topics: Cell Differentiation; Colonic Neoplasms; Humans; Lysosomal Storage Diseases; Lysosomes; Suramin; Tum | 1990 |
Suramin-induced differentiation of the human colic adenocarcinoma cell clone HT29-D4 in serum-free medium.
Topics: Adenocarcinoma; Carcinoembryonic Antigen; Cell Count; Cell Differentiation; Cell Division; Clone Cel | 1990 |
Impaired carcinoembryonic antigen release during the process of suramin-induced differentiation of the human colonic adenocarcinoma cell clone HT29-D4.
Topics: Adenocarcinoma; Carcinoembryonic Antigen; Cell Membrane; Cell Transformation, Neoplastic; Colonic Ne | 1990 |
The concentration of glucose in the culture medium determines the effect of suramin on the growth and differentiation of the human colonic adenocarcinoma cell clone HT29-D4.
Topics: Adenocarcinoma; Colonic Neoplasms; Culture Media; Glucose; Humans; In Vitro Techniques; Microscopy, | 1990 |
Suramin inhibits cell growth and glycolytic activity and triggers differentiation of human colic adenocarcinoma cell clone HT29-D4.
Topics: Adenocarcinoma; Alkaline Phosphatase; Cell Differentiation; Cell Division; Cell Line; Colonic Neopla | 1989 |
Proliferation of the human colon carcinoma cell line HT29: autocrine growth and deregulated expression of the c-myc oncogene.
Topics: Blotting, Northern; Blotting, Southern; Carcinoma; Cell Differentiation; Cell Division; Colonic Neop | 1989 |
Autocrine secretion of a colorectum-derived growth factor by HT-29 human colon carcinoma cell line.
Topics: Carcinoma; Colonic Neoplasms; Epidermal Growth Factor; ErbB Receptors; Growth Substances; Humans; Su | 1988 |